| |||||||
  | |||||||
| 1 | SENATE RESOLUTION | ||||||
| 2 |     WHEREAS, Serious mental illnesses like bipolar disorder,  | ||||||
| 3 | major depressive disorder, and schizophrenia often require  | ||||||
| 4 | treatment with antipsychotic medications for effective  | ||||||
| 5 | management, and antipsychotic prescribing rates continue to  | ||||||
| 6 | rise; and | ||||||
| 7 |     WHEREAS, While prolonged antipsychotic use may be  | ||||||
| 8 | essential for the treatment of certain conditions, it is  | ||||||
| 9 | associated with tardive dyskinesia (TD), a condition marked by  | ||||||
| 10 | uncontrollable, abnormal, and repetitive movements of the  | ||||||
| 11 | face, torso, limbs, or extremities; and | ||||||
| 12 |     WHEREAS, People at higher risk of TD include those older  | ||||||
| 13 | than 55 years, people who are Black, women, individuals with  | ||||||
| 14 | mood or substance use disorders, intellectual disabilities, or  | ||||||
| 15 | central nervous system injuries, and those with high  | ||||||
| 16 | cumulative antipsychotic exposure; and | ||||||
| 17 |     WHEREAS, Approximately 60% of the estimated 800,000 U.S.  | ||||||
| 18 | adults living with TD remain undiagnosed, and even mild TD  | ||||||
| 19 | symptoms can be stigmatizing and impair physical, social, and  | ||||||
| 20 | emotional well-being, underscoring the urgency of early  | ||||||
| 21 | screening, detection, and intervention; and | ||||||
 
  | |||||||
  | |||||||
| 1 |     WHEREAS, The American Psychiatric Association recommends  | ||||||
| 2 | routine TD screening in their clinical guidelines for  | ||||||
| 3 | antipsychotic treatment, and individuals treated with  | ||||||
| 4 | antipsychotics or experiencing abnormal movements should  | ||||||
| 5 | consult their health care providers to assess TD risk, receive  | ||||||
| 6 | TD screenings, and determine appropriate treatment together;  | ||||||
| 7 | and | ||||||
| 8 |     WHEREAS, FDA-approved treatments for TD can provide  | ||||||
| 9 | options for symptom management and improved quality of life  | ||||||
| 10 | for many individuals living with TD; and | ||||||
| 11 |     WHEREAS, The General Assembly can encourage TD screening  | ||||||
| 12 | education and awareness for health care providers, patients,  | ||||||
| 13 | and care partners to help ensure patients prescribed  | ||||||
| 14 | antipsychotics receive care and support that aligns with  | ||||||
| 15 | clinical best practices, including regular TD screenings;  | ||||||
| 16 | therefore, be it | ||||||
| 17 |     RESOLVED, BY THE SENATE OF THE ONE HUNDRED FOURTH GENERAL  | ||||||
| 18 | ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 4  | ||||||
| 19 | through May 10, 2025 as Tardive Dyskinesia Awareness Week  | ||||||
| 20 | (TDAW) in the State of Illinois; and be it further | ||||||
| 21 |     RESOLVED, That we support TDAW in recognition of the  | ||||||
| 22 | importance of early detection and intervention to improve  | ||||||
 
  | |||||||
  | |||||||
| 1 | outcomes for people living with mental health conditions and  | ||||||
| 2 | prescribed antipsychotics, and we support efforts to raise  | ||||||
| 3 | awareness about the causes and symptoms of tardive dyskinesia  | ||||||
| 4 | (TD) and the importance of routine TD screening. | ||||||